|
|
|
| The Clinical Use and Insurance of Biosimilars in the US ——Taking the Pfizer vs. Johnson Lawsuit as an Example |
DONG Xin-yue,JIANG Rong,LIZHA Adelietibieke,SHAO Rong( ) |
| The Research Center of National Drug Policy & Ecosystem, China Pharmaceutical University, Nanjing 211198, China |
|
|
|
Abstract In recent years, the global development of biosimilars is in full swing. Governments have introduced a series of incentive policies to promote the development and application of biosimilars, in addition, large-scale pharmacy enterprises have also seized biosimilars’ market opportunities through the acquisition of other small and medium-sized biopharmaceutical companies. The Pfizer vs. Johnson lawsuit was taken as a research object, and the overall description of American biosimilars insurance policies, development process of litigation case and in-depth analysis of series focus issues were carried out. The study found that the competitive pressures from the original companies and the clinical conservative attitudes towards the substitutability of biosimilars threaten the application and promotion of biosimilars to a certain extent, while its price advantage and increasingly clear policy environment make the future of biosimilars promising.
|
|
Received: 13 April 2019
Published: 15 January 2020
|
|
|
|
Corresponding Authors:
Rong SHAO
E-mail: shaorong118@163.com
|
|
|
| [1] |
FDA. U . S. food & drug administration.[2018-12-04]..
|
|
|
| [2] |
Sagonowsky E . With its Remicade biosimilar stymied by the brand, Pfizer sues Johnson & Johnson for ‘anticompetitive’ dealmaking. [2017-09-20/2018-12-01].
|
|
|
| [3] |
Ashbridge B . Biosimilars council sides with Pfizer in Antitrust dispute with J&J. [2018-02-04/2018-12-03].
|
|
|
| [4] |
Nicholas Simmons-Stern, Christina Danosi, Alexandra Haber , et al. The State of US Biosimilars Market Access: Payer Perceptions of Past, Present, and Future Hurdles to Adoption.[2018-01/2018-12]. .
|
|
|
| [5] |
中国财经网. 辉瑞“起诉”强生不正当竞争. [2017-09-27/2018-11-30]. .
|
|
|
| [5] |
CFi.CN. Pfizer “Sues” Johnson for Unfair Competition. [2017-09-27/2018-11-30]. .
|
|
|
| [6] |
医线 . 生物类似药研发势头大增,进入市场却受限制. [2016-04-01/2018-03-15]. .
|
|
|
| [6] |
Medical Line. R&D of Biosimilars Increased Dramatically, But the Marketing Access was Limited. [2016-04-01/2018-03-15]. .
|
|
|
| [7] |
陈永法, 王翠玲, 伍琳 . 美国生物类似药研发与上市制度及对我国的启示. 中国医药工业杂志, 2016,47(10):1333-1338.
|
|
|
| [7] |
Chen Y F, Wang C L, Wu L . The research and development and the marketing approval system of the biosimilars in the United States and its enlightenment. Chinese Journal of Pharmaceuticals, 2016,47(10):1333-1338.
|
|
|
| [8] |
Medicare.GOV. What Medicare Covers. [2018-12-04]..
|
|
|
| [9] |
Brennan Z . Pfizer Sues J&J over contracts blocking Remicade biosimilars. [2017-09-20/2018-12-01].
|
|
|
| [10] |
Shapland L . Inflectra launch: a medicare data perspective. [2018-01-21/2018-12-04].
|
|
|
| [11] |
Silbersher Z . What are the takeaways from the Remicade? antitrust decision between Pfizer and J&J. [2018-08-16/2018-12-03].
|
|
|
| [12] |
EY. Global biosimilar policy comparison.[2017-08-14/2019-01-14].
|
|
|
| [13] |
Centers for Medicare and Medicaid Services . Medicare program; contract year 2019 policy and technical changes to the medicare advantage, medicare cost plan, medicare fee-for-service, the medicare prescription drug benefit programs, and the PACE program. Fed Regist, 2017,82(227):56336-56527.
|
|
|
| [14] |
Rockoff J D . Pfizer plans to launch remicade biosimilar in november. [2016-10/2018-12].The Wall Street Journal. .
|
|
|
| [15] |
CRS. Biologics and Biosimilars: Background and Key Issues.[2017-12-27/2018-12-03].
|
|
|
| [15] |
c4c4f5c.pdf.
|
|
|
| [16] |
朗迦 . “捆绑销售”都是垄断吗. 经济世界, 2001,8(12):12-13.
|
|
|
| [16] |
Lang J . Are bundled sales monopolies. Business World, 2001,8(12):12-13.
|
|
|
| [17] |
Abrams L W . Biosimilars & exclusive dealing antitrust law: Pfizer (Inflectra) v J&J (Remicade). [2017-10-30/2018-12-01].
|
|
|
| [18] |
Davio K . Biosimilars Council Backs Pfizer with amicus brief in ongoing infliximab case. [2018-01-29/2018-12-01].
|
|
|
| [19] |
The Competition Bureau . Competition Bureau statement regarding its inquiry into alleged anti-competitive conduct by Janssen. [2019-02-20/2019-04-05]..
|
|
|
| [20] |
Southey F . Motion to dismiss Inflectra case denied, but J&J insists ‘Pfizer’s lawsuit is without merit’. [2018-08-14/2018-12-04].
|
|
|
| [21] |
Hovenkamp H J, Hovenkamp E N . Complex bundled discounts and antitrust policy, Buffalo Law Review, 2009,57(3):1227-1249.
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
